Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
Terns Pharmaceuticals (Nasdaq: TERN) announced its participation in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 12:50 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Terns Pharmaceuticals (Nasdaq: TERN) announced its participation in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 12:50 PM ET. The event will address serious diseases, including NASH and obesity, which are central to Terns' clinical focus. A live webcast will be accessible on Terns' investor relations page, with a replay available for 30 days post-presentation. The company is advancing a pipeline featuring small-molecule therapies and combination treatments aimed at improving patient outcomes.
Details
News Market Reaction – TERN
The recorded move for TERN in the trading session of this news was +3.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity, today announced that management will be participating in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8 at 12:50pm ET.
A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.